21 completed, 7 active not recruiting, 7 terminated, 5 recruiting. 15 Phase 2, 12 Phase 3, 8 Phase 1, 7 Not applicable, 4 Phase 4.
Follow Histamine Antagonists: new trials by email Literature Review of Histamine Antagonists trials Research Report on Histamine Antagonists
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study IV glucocorticoid and antihistamine, IV glucocorticoid and antihistamine (standard of care) - Allergic Reaction to Contrast Media, Hypersensitivity Reaction | Not applicable | Not yet recruiting | Paul Peng, MD PhD MSCR | 540 | 2026-06-01 | 2026-02-19 |
| Steroid Use in Treatment of Allergic Reactions to Food Antihistamines, Systemic corticosteroids, Adrenaline (rescue medication) - Anaphylactic Reaction, Anaphylaxis | Phase 4 | Recruiting | Johannes Trueck | 160 | 2026-01-26 | 2026-01-27 |
| A Prospective, Randomized, Controlled Study Comparing the Efficacy of Intranasal Corticosteroids (INCS) Combined With Intranasal Antihistamines (INAH) and INCS Combined With Oral Antihistamines (OAH) in the Treatment of Moderate to Severe Allergic Rhinitis Symptoms Intranasal corticosteroids (INCS) combined with oral antihistamines (OAH) used for treatment, Intranasal corticosteroids (INCS) combined with nasal antihistamines (INAH) used for treatment. - Allergic Rhinitis | Phase 4 | Not yet recruiting | China-Japan Union Hospital | 50 | 2026-01-01 | 2025-12-19 |
| Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex, IHC (Histoglob) in Chronic Urticaria Antihistaminics, H2 blockers, Leukotriene antagonists, Immunoglobulin/Histamine Complex (IHC) Injection - Chronic Urticaria | Completed | Bharat Serums and Vaccines Limited | 660 | 2025-12-31 | 2026-10-02 | |
| Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion VPAT (Vibratory Positive Pressure Therapeutic Apparatus）, basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA, OPEP（Oscillating Positive Expiratory Pressure device） - Atopic Rhinitis, Atopic Asthma | Not applicable | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 200 | 2025-08-01 | 2025-08-11 |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 770 | 2025-04-09 | 2026-10-13 |
| Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine - Lung Neoplasm Malignant | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 60 | 2025-03-20 | 2026-10-13 |
| Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) Sacituzumab tirumotecan, Pemetrexed, Carboplatin - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 550 | 2024-06-11 | 2026-09-11 |
| Prospective Multicenter Observational Study and Promotion of the Application of Focused Ultrasound in Allergic Rhinitis High-intensity focused ultrasound (HIFU), intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines - Allergic Rhinitis | Early Phase 1 | Unknown | Chongqing Medical University | 240 | 2023-08-01 | 2024-02-22 |
| A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) Paclitaxel, Irinotecan, Pembrolizumab - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 230 | 2023-05-16 | 2026-10-07 |
| Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients Laronidase, Antihistamine, Antipyretic - Mucopolysaccharidosis Type 1 | Phase 3 | Completed | Cinnagen | 12 | 2022-09-10 | 2024-08-06 |
| Effects of Systemic Drugs on Intraocular Pressure Antihypertensive Agents, Antihistaminics - Glaucoma, Angle-Closure, Glaucoma Suspect | Unknown | Benha University | 200 | 2022-04-07 | 2022-04-14 | |
| 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Irinotecan, Temozolomide, Bevacizumab - Recurrent Medulloblastoma, Recurrent Ependymoma | Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 62 | 2022-04-04 | 2026-07-28 |
| Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) UX053, Placebo, Antipyretic - Glycogen Storage Disease Type III | Phase 1 / Phase 2 | Terminated | Ultragenyx Pharmaceutical Inc | 9 | 2021-10-18 | 2024-04-16 |
| Use of the Modified PUQE Score on Admitted Cases of Hyperemesis Gravidarum (HG) to Guide Response to Treatment Antiemetic Combinations - Hyperemesis Gravidarum | Completed | Tasnem Abo-elouon | 200 | 2021-09-05 | 2023-04-05 | |
| Histamine as a Molecular Transducer of Adaptation to Exercise Aerobic Exercise, alpha-FMH, Resistance and Aerobic Exercise - Postexercise Hypotension | Early Phase 1 | Active not recruiting | University of Oregon | 80 | 2021-07-28 | 2026-01-23 |
| C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients. Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins, Oral low dose steroid, Intravenous Antibiotics with Low dose steroid. - COVID -19 | Not applicable | Completed | Manimarane Arjunan, MD,DM (Cardiology) | 25 | 2021-04-15 | 2021-06-23 |
| Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project) Capsaicin, Diphenhydramine, Morphine Chloride - Itch | Not applicable | Completed | Aalborg University | 26 | 2021-01-18 | 2022-01-27 |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) Ocrelizumab, Antihistamine, Methylprednisolone - Multiple Sclerosis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 769 | 2020-12-03 | 2026-07-24 |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) Ocrelizumab, Antihistamine, Methylprednisolone - Multiple Sclerosis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 864 | 2020-11-26 | 2026-09-28 |
Showing 20 of 50. Sign in to see all of them.
Hepatitis B (5) · COVID-19 (3) · Chronic Urticaria (3) · Rhinitis, Allergic (3) · Hypersensitivity (2) · Lung Neoplasms (2) · Multiple Sclerosis (2) · Multiple Sclerosis, Chronic Progressive (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Anaphylaxis (1) · Arthritis, Rheumatoid (1) · Breast Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Carcinoma in Situ (1) · Carcinoma, Non-Small-Cell Lung (1)
Arrowhead Pharmaceuticals (5) · Merck Sharp & Dohme LLC (4) · Genentech, Inc. (3) · Hoffmann-La Roche (3) · National Cancer Institute (NCI) (3) · Consorci Sanitari de Terrassa (2) · University of Cincinnati (2) · Aalborg University (1) · Benha University (1) · Bharat Serums and Vaccines Limited (1) · Children's Hospital Medical Center, Cincinnati (1) · China Medical University Hospital (1) · China-Japan Union Hospital (1) · Chongqing Medical University (1) · Chulalongkorn University (1)
United States (22) · China (8) · Germany (8) · South Korea (8) · Spain (8) · Italy (7) · Canada (6) · Poland (6) · Thailand (6) · Switzerland (5) · Taiwan (5) · Turkey (Türkiye) (5) · Argentina (4) · Australia (4) · Brazil (4)
Ali Rabani, Professor (1) · Anish Thomas, M.D. (1) · Chun-Chih Lin, Professor (1) · David Bernstein, MD (1) · Deborah Hurst, M.D. (1) · Dr Saswata Banerjee (1) · Dr. Tasnee Chonmaitree (1) · E. Steve Woodle, MD (1) · Edward R. Conner, M.D. (1) · Gurjit K Khurana Hershey, MD, PhD (1)
PMID 39459868, PMID 42208560, PMID 10380774, PMID 12773705, PMID 1532808, PMID 1593914, PMID 15992574, PMID 16088266, PMID 16606412, PMID 16960636, PMID 17561703, PMID 17968683, PMID 18002246, PMID 19602651, PMID 19885944, PMID 19964539, PMID 20816182, PMID 22430337, PMID 22934336, PMID 23406588, PMID 23430080, PMID 23710948, PMID 24535140, PMID 24589166, PMID 24991883, PMID 26054553, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 29655772, PMID 3410585, PMID 35123074, PMID 35642432, PMID 36081814, PMID 38088821, PMID 38152462, PMID 39770791, PMID 40508884, PMID 40830667, PMID 41060318, PMID 41754542, PMID 42376811, PMID 42820295, PMID 8120268, PMID 8608748, PMID 9072139, PMID 9578914
2023 (6), 2014 (3), 2015 (2), R01DC002620 (1), UM1CA081457 (1)